21590 ⎘
Preparations containing radioactive substances for use in therapy or testing characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus; Organic compounds; Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins; Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
#2MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY
#3BINDING AGENT RECOGNITION OF DRUG-PEPTIDE CONJUGATES
#4COMPOSITIONS TARGETING ENDOTHELIAL CELLS AND USES THEREOF
#55T4 BINDING POLYPEPTIDES AND USES THEREOF
#6NANOBODY BASED IMAGING AND TARGETING OF ECM IN DISEASE AND DEVELOPMENT
#7METHODS OF ENHANCING EFFICACY OF IMMUNOCONJUGATES USING PAIRED HUMAN ANTIBODIES TARGETED AT NON-OVERLAPPING B-CELL EPITOPES ON THE SAME ANTIGEN
#8HER3 NANOBODIES
#9DOTA-HAPTEN COMPOSITIONS FOR ANTI-DOTA/ANTI-TUMOR ANTIGEN BISPECIFIC ANTIBODY PRETARGETED RADIOIMMUNOTHERAPY
#10PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY
#11RADIOIMMUNOCONJUGATES TARGETING PHOSPHATIDYLSERINE FOR USE IN THE TREATMENT OF CANCER
#12ANTIBODY-DRUG CONJUGATES AND USES THEREOF
#13HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS
#14Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
#15METHODS AND COMPOSITIONS FOR TARGETING DISEASE RELATED CELL SURFACE RECEPTORS USING RADIOLABELED AND/OR CYTOTOXIN LABELLED ANTIBODIES
#16Treatment of Proliferative Disorders Using Antibodies to PSMA
#17USE OF ANTI-B7H3 ANTIBODIES FOR TREATING CANCER IN THE CENTRAL NERVOUS SYSTEM
#18EGFRVIII-TARGETED COMPOUNDS AND USES THEREOF
#19REAGENTS FOR SITE-SPECIFIC LABELING OF PROTEINS WITH RADIOHALOGENS, AND METHODS OF MAKING AND USING THE SAME
#20Antibody-drug conjugates and uses thereof
#21ANTIBODIES AGAINST CAIX WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR
#22RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
#23ANTI-CLDN18.2 ANTIBODY CONJUGATES
#24RADIOLABELED PARP INHIBITOR CONJUGATES FOR CANCER TREATMENT
#25THERAPEUTIC CONJUGATES
#26Chemoselective Rapid Azo-Coupling Reaction for Bioconjugation
#27ANTIBODIES BINDING TROP2 AND USES THEREOF
#28Nanobody Target MSLN and Uses in Chimeric Antigen Receptor Cell Therapy
#29HUMANISED ANTIBODIES LABELLED WITH RADIONUCLIDES THAT EMIT BETA-RAYS
#30METHODS AND COMPOSITIONS RELATED TO ANTIBODY FRAGMENTS THAT BIND TO TUMOR-ASSOCIATED GLYCOPROTEIN 72 (TAG-72)
#31ANTIGEN-BINDING PROTEIN CONSTRUCTS AND ANTIBODIES AND USES THEREOF
#32METHODS OF TREATING NEOPLASTIC ASTROCYTOMA
#33LRRC15 ANTIBODIES AND CONJUGATES THEREOF
#34MOF FOR RADIOTHERAPY
#35HER2 ANTIBODY AND APPLICATION THEREOF
#36CONJUGATES ENHANCING TOTAL CELLULAR ACCUMULATION
#37Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
#38NANOBODIES BINDING TROP2 AND USES THEREOF
#39REACTIONS OF RADIOACTIVE COMPOUNDS FACILITATED BY A SOLID PHASE
#40NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A
#41One-Step Labeling of Antibodies to High Specific Activity with Actinium-225
#42DNA Damage Repair Deficit in Cancer Cells
#43NANOBODY BASED IMAGING AND TARGETING OF ECM IN DISEASE AND DEVELOPMENT
#44B7H3 Antibodies with Chelators
#45RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY
#46METHODS OF TREATING SKIN CANCER BY ADMINISTERING A PD-1 INHIBITOR
#47METHODS OF IMAGING USING MULTIPLE IMAGING AGENTS
#48CYSTEINE LINKED NANOBODY DIMERS
#49PROCESS FOR SITE-SPECIFIC MODIFICATION OF AN ANTIBODY
#50ANTI-FCRH5 ANTIBODIES
#51RI-LABELED HUMANIZED ANTIBODY
#52A DOTA binding chimeric antigen receptor for cellular therapy
#53Pharmaceutical compositions and related methods of delivery
#54Pharmaceutical compositions and related methods of delivery
#55ANTIBODIES AGAINST CAIX WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR
#56NOVEL THERANOSTIC AGENTS FOR PSMA POSITIVE CANCERS
#57IMMUNOPET AND IMMUNOSPECT IMAGING TO IDENTIFY CYTOTOXIC T CELL ACTIVITY
#58COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER
#59HUMANIZED ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF
#60METHODS AND COMPOSITIONS FOR DETERMINING THE BIODISTRIBUTION OF ACTIVATABLE ANTI-CD166 ANTIBODY CONJUGATES
#61Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
#62PRAME BINDING MOLECULES AND USES THEREOF
#63Antibody and functional fragment thereof
#64Actinium-225 and checkpoint inhibitor combination therapy
#65Humanised Anti Kallikrein-2 Antibody
#66ANTIBODY-DRUG CONJUGATES AND USES THEREOF
#67PHOTOCROSSLINKING PEPTIDES FOR SITE SPECIFIC CONJUGATION TO FC-CONTAINING PROTEINS
#68REAGENT FOR BIOCONJUGATION VIA IRREVERSIBLE REBRIDGING OF DISULFIDE LINKAGES
#69Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand
#70Ri-labeled humanized antibody
#71N-acetylgalactosamino dendron-clearing agent for dota-pretargeted radioimmunotherapy
#72Detection and Treatment of Malignant Tumours in the CNS
#73RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY
#74PD-L 1-BINDING POLYPEPTIDE AND USE THEREOF
#75Methods and compositions for targeting disease related cell surface receptors using radiolabeled and/or cytotoxin labelled antibodies
#76COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES
#77Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy
#78Automatic process platform for the production of astatine-211 [At-211]-radiopharmaceuticals
#79Method and Kit for Treating Brain Tumor by using an Ultrasound System
#80Antibody-drug conjugates and uses thereof
#81Residualizing linkers and uses thereof
#82METHODS OF TREATING NEOPLASTIC ASTROCYTOMA
#83Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
#84Pharmaceutical compositions and related methods of delivery
#85RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
#86Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
#87Anti-CD146 antibodies and uses thereof
#88Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
#89NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A
#90Antibody-drug conjugates and uses thereof
#91Anti-CD33 antibody-guided imaging and treatment of acute myeloid leukemia
#92ANTI-MESOTHELIN RADIOLABELLED SINGLE DOMAIN ANTIBODIES SUITABLE FOR THE IMAGING AND TREATMENT OF CANCERS
#93USE OF ANTI-B7H3 ANTIBODIES FOR TREATING CANCER IN THE CENTRAL NERVOUS SYSTEM
#94Anti-FCRH5 antibodies
#95Method of treating renal cancer using carbonic anhydrase IX (G250) antibodies
#96Antibody-drug conjugates and uses thereof
#97Methods of treating skin cancer by administering a PD-1 inhibitor
#98Amnion coated embolic agents for treating tumors
#99Nanobody based imaging and targeting of ECM in disease and development
#100Humanised anti kallikrein-2 antibody
#101Nanobody dimers linked via C-terminally engineered cysteins
#102T-CELL RECEPTOR MIMIC (TCRM) ANTIBODIES
#103NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER
#104Anti-Ly6E antibodies and methods of use
#105RS7 Antibodies
#106Methods and materials for treating tumors
#107Treatment of Proliferative Disorders Using Antibodies to PSMA
#108Antibody-drug conjugates and uses thereof
#109PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY
#110Therapeutic antibodies and uses thereof
#111Isotope purification method
#112Chemoselective rapid azo-coupling reaction for bioconjugation
#113RS7 antibodies
#114Detection and treatment of malignant tumours in the CNS
#115Automatic process platform for the production of astatine-211 [At 211] radiopharmaceuticals
#116Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
#117Systems and methods for determining optimum patient-specific antibody dose for tumor targeting
#118RS7 antibodies
#119Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
#120Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
#121Multivalent Antibody Complexes Targeting IGF-1R Show Potent Toxicity Against Solid Tumors
#122Carbonic anhydrase IX (G250) antibodies and methods of use thereof
#123NON-INVASIVE IMAGING OF TUMOR PD-L1 EXPRESSION
#124METHODS OF TREATING MENINGIOMA
#125Methods and compositions related to single chain antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
#126RADIO-LABELLED ANTIBODY FRAGMENTS FOR USE IN THE PROGNOSIS, DIAGNOSIS OF CANCER AS WELL AS FOR THE PREDICTION OF CANCER THERAPY RESPONSE
#127Cysteine linked nanobody dimers
#128Methods of treating skin cancer by administering a PD-1 inhibitor
#129COMBINATION OF ANTI-PD-1 ANTIBODIES AND RADIATION TO TREAT CANCER
#130Alpha-emitting complexes
#131Antibodies to GRP78
#132Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells
#133RS7 antibodies
#134Stable compositions of high-concentration allotype-selected antibodies for small-volume administration
#135Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
#136USES OF ANTI-HER3 ANTIBODIES FOR TREATING CANCER
#137Method to visualize very early stage neoplasm or other lesions
#138One-step labeling of antibodies to high specific activity with actinium-225
#139Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use
#140Anti-Ly6E antibodies and methods of use
#141METHODS OF TREATING PROSTATE CANCER WITH ANTI-PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODIES
#142Antibody-drug conjugates and uses thereof
#143Humanised anti kallikrein-2 antibody
#144Radio-imaging and radio-therapy of cancer using antibodies to HAAH
#145ANTIBODIES REACTIVE WITH AN EPITOPE LOCATED IN THE N-TERMINAL REGION OF MUC5AC COMPRISING CYSTEINE-RICH SUBDOMAIN 2 (CYS2)
#146Tumor vascular marker-targeted vaccines
#147Antibodies that bind OV064 and methods of use therefor
#148Residualizing linkers and uses thereof
#149Radiopharmaceutical solutions with advantageous properties
#150Monoclonal antibody and derivatives
#151Monoclonal antibodies to human 14-3-3 epsilon and human 14-3-3 epsilon sv
#152Methods and compositions related to single chain antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
#153Pharmaceutical compositions and related methods of delivery
#154ANTIGEN-BINDING PROTEINS SPECIFIC FOR HLA-A2-RESTRICTED WILMS TUMOR 1 PEPTIDE
#155GLIOBLASTOMA MULTIFORME-REACTIVE ANTIBODIES AND METHODS OF USE THEREOF
#156Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#157Antigen associated with the neovasculature of tumour metastases
#158Monoclonal antibody against necrosis marker PRDX4 and use thereof
#159High affinity anti-GD2 antibodies
#160Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
#161Method for Treating Cancers by Alternating Immunotherapeutics and Directly Oncolytic Therapeutics
#162INACTIVE N-ACETYLATED-ALPHA-LINKED ACIDIC DIPEPTIDASE-LIKE PROTEIN 2 (NAALADL2) AS A THERAPEUTIC AND DIAGNOSTIC TARGET
#163Anti-TAT226 antibodies and immunoconjugates
#164Antibody-drug conjugates and uses thereof
#165RECEPTOR BINDING CONJUGATES
#166ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR ANTIBODIES FOR DIAGNOSTIC AND CLINICAL APPLICATIONS
#167Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#168Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#169Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#170Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#171Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#172Antibodies and immunoconjugates and uses therefor
#173Antibody against transporter and use thereof
#174Anti-Ly6E antibodies and methods of use
#175Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
#176Anti-FcRH5 antibodies
#177LM-antibodies, functional fragments, LM-1 target antigen, and methods for making and using same
#178NUCLEOTIDE AND PROTEIN SEQUENCES OF AN ANTIBODY DIRECTED AGAINST AN EPITOPE COMMON TO HUMAN ACIDIC AND BASIC FERRITINS, MONOCLONAL ANTIBODIES OR ANTIBODY-LIKE MOLECULES COMPRISING THESE SEQUENCES AND USE THEREOF
#179Treatment of Proliferative Disorders Using Antibodies to PSMA
#180Nucleic acids encoding human antibodies to sialyl-lewis
#181Combination therapy with anti-CD74 and anti-CD20 antibodies provides enhanced toxicity to B-cell diseases
#182Pharmaceutical compositions and related methods of delivery
#183Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
#184Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
#185Compositions and methods for the diagnosis and treatment of tumor
#186Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
#187Anti-Trop-2 antibody-drug conjugates and uses thereof
#188Anti-mucin antibodies for early detection and treatment of pancreatic cancer
#189METHOD FOR COMBINED IMAGING AND TREATING ORGANS AND TISSUES
#190Methods for suppressing cancer by inhibition of TMCC3
#191Antibodies that bind OV064 and methods of use therefor
#192Antibodies to TIP-1
#193Targeted carriers for drug delivery across the gastrointestinal epithelium
#194RS7 antibodies
#195Immuno imaging agent for use with antibody-drug conjugate therapy
#196Immuno imaging agent for use with antibody-drug conjugate therapy
#197Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#198Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#199Diagnosis and treatment of cancer using anti-GPR49 antibody
#200Anti-mucin antibodies for early detection and treatment of pancreatic cancer
#201In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
#202Tumor-specific recognition molecules
#203Chimeric T cell receptor comprising carbonic anhydrase IX (G250) antibody
#204Anti-LGR5 antibodies and immunoconjugates
#205Thiol-ene click chemistry for drug conjugates
#206DETECTING AND TREATING SOLID TUMORS THROUGH SELECTIVE DISRUPTION OF TUMOR VASCULATURE
#207Antibodies and immunoconjugates and uses therefor
#208Alpha emitting constructs and uses thereof
#209Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
#210Antigen associated with the neovasculature of tumour metastases
#211Agents for clearing biomolecules from circulation
#212NOVEL ANTIGEN ASSOCIATED WITH THE NEOVASCULATURE OF TUMOUR METASTASES
#213Alpha-emitting complexes
#214Anti-TAT226 antibodies and immunoconjugates
#215Molecular imaging of cancer cells in vivo
#216Multiple signaling pathways induced by hexvalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
#217Antibodies that bind OV064 and methods of use therefor
#218Antigen associated with the neovasculature of tumour metastases
#219Monoclonal antibody against necrosis marker ERP29 and use thereof
#220Antibodies Against A Cancer-Associated Epitope of Variant HNRNPG and Uses Thereof
#221RADIOLABELED AFFIBODY MOLECULES
#222Monoclonal antibody against necrosis marker PRDX4 and use thereof
#223Ultrafiltration concentration of allotype selected antibodies for small-volume administration
#224Monoclonal antibodies against PCBP-1 antigens, and uses therefor
#225Targeted carriers for drug delivery across the gastrointestinal epithelium
#226METHOD FOR COMBINED IMAGING AND TREATING ORGANS AND TISSUES
#227Specific binding proteins and uses thereof
#228Tumor-specific recognition molecules
#229Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
#230Anti-mucin antibodies for early detection and treatment of pancreatic cancer
#231RS7 antibodies
#232Anti-TAT226 antibodies and immunoconjugates
#233Pharmaceutical compositions and related methods of delivery
#234LIGANDS TO RADIATION-INDUCED MOLECULES
#235In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
#236Glioblastoma multiforme-reactive antibodies and methods of use thereof
#237PRETARGETING KIT, METHOD AND AGENTS USED THEREIN
#238Antibody therapy
#239Tumor vascular marker-targeted vaccines
#240IL-18 RECEPTOR AS A NOVEL TARGET OF REGULATORY T CELLS IN CANCER
#241Cancerous disease modifying antibodies
#242Pharmaceutical compositions and related methods of delivery
#243SPECIFIC BINDING PROTEINS AND USES THEREOF
#244Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
#245SPECIFIC BINDING PROTEINS AND USES THEREOF
#246Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
#247PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY
#248Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
#249Compositions and methods for the diagnosis and treatment of tumor
#250Antibody therapy
#251Diagnosis and treatment of cancer using anti-GPR49 antibody
#252Methods to determine immunogenicity of humanized anti-tag 72 CC49 antibodies
#253Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
#254METHODS OF INDUCING AN IMMUNE RESPONSE
#255Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-EGP-2 scFv fragment
#256Anti-Tumor Cell Antigen Antibody Therapeutics
#257METHOD OF TREATING IMMUNE DISEASE USING B-CELL ANTIBODIES
#258METHODS TO INHIBIT CELL GROWTH
#259SPECIFIC BINDING PROTEINS AND USES THEREOF
#260APPARATUS AND METHOD FOR PREPARING MEDICINES CONTAINING RADIOACTIVE SUBSTANCES
#261MODIFIED ANTIBODIES AND METHODS OF USE
#262CANCER STEM CELL EXPRESSION PATTERNS AND COMPOUNDS TO TARGET CANCER STEM CELLS
#263METHOD FOR IMAGING TUMOR TISSUE
#264LM-1 ANTIBODIES, FUNCTIONAL FRAGMENTS, LM-1 TARGET ANTIGEN, AND METHODS FOR MAKING AND USING SAME
#265Antibodies against a cancer-associated epitope of variant HnRNPG and uses thereof
#266Variants of humanized anti-carcinoma MAb CC49
#267Treatment of Proliferative Disorders Using Antibodies to PSMA
#268Alpha-emitting constructs and uses thereof
#269Monoclonal Antibodies Against PCBP-1 Antigens, and Uses Therefor
#270Vimentin Directed Diagnostics And Therapeutics For Multidrug Resistant Neoplastic Disease
#271Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
#272Radiolabeled affibody molecules
#273Antibodies that bind GalNAc1-3Gal, pharmaceutical compositions and methods of using same
#274Antigen associated with the neovasculature of tumour metastases
#275Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
#276ANTIBODY RECOGNIZING ANTIGEN
#277Method for preparation of single chain antibodies
#278PEPTIDES FOR TREATING AND DIAGNOSING CANCERS AND METHODS FOR USING THE SAME
#279RS7 antibodies
#280Antibody therapy
#281Radionuclides for medical use
#282SITE-SPECIFIC CONJUGATION OF LIGANDS TO NANOPARTICLES
#283Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
#284Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
#285Radiotherapeutic High Specific Activity Tin-117m and Methods of Use
#286Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
#287Chimeric, human and humanized anti-CSAP monoclonal antibodies
#288DIAGNOSIS AND TREATMENT OF CANCER BY USING ANTI-PRG-3 ANTIBODY
#289PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY
#290ANTIBODIES AGAINST A PROTEIN ENTITLED 161P2F10B
#291Method of determining the course of treatment for a patient having adenocarcinoma
#292System, method, computer-readable medium, and use for planning combined therapy
#293RG1 ANTIBODIES AND USES THEREOF
#294SPECIFIC BINDING PROTEINS AND USES THEREOF
#295COMBINATION THERAPY IN THE TREATMENT OF CANCER
#296ANTIBODIES AND RELATED MOLECULES THAT BIND TO 58P1D12 PROTEINS
#297Cripto binding molecules
#298Diagnosis and treatment of cancer using anti-EREG antibody
#299Nucleic acids encoding humanized anti-tag 72 CC49 antbodies
#300Method For Treating Cancer